Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down - Should You Sell?

Key Points

• Daiichi Sankyo shares experienced a significant gap down in trading, opening at $23.83 after closing at $24.69, and last traded at $24.04.
• Analysts have raised the stock's rating to a "strong-buy", with a current consensus rating reflecting strong positive sentiment for the company.
• Daiichi Sankyo has a market cap of $45.61 billion and notable financial metrics including a price-to-earnings ratio of 23.38 and a low debt-to-equity ratio of 0.06.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $24.69, but opened at $23.83. Daiichi Sankyo shares last traded at $24.04, with a volume of 10,759 shares.

Wall Street Analysts Forecast Growth

Separately, Nomura Securities raised Daiichi Sankyo to a "strong-buy" rating in a report on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Daiichi Sankyo has a consensus rating of "Strong Buy".

Daiichi Sankyo Stock Down 2.7%

The stock has a market cap of $44.19 billion and a PE ratio of 22.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The company has a 50 day moving average price of $24.48 and a two-hundred day moving average price of $24.22.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.